Generation Bio Co. (NASDAQ:GBIO) Sees Significant Growth in Short Interest

Generation Bio Co. (NASDAQ:GBIO) was the recipient of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 7,952 shares, a growth of 284.5% from the January 15th total of 2,068 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 127,651 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 127,651 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the company’s stock are short sold.

Hedge Funds Weigh In On Generation Bio

A number of institutional investors have recently made changes to their positions in GBIO. Acadian Asset Management LLC boosted its stake in Generation Bio by 54.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after purchasing an additional 407,843 shares during the period. Militia Capital Partners LP acquired a new position in shares of Generation Bio in the second quarter valued at $174,000. Y Intercept Hong Kong Ltd bought a new position in Generation Bio in the second quarter worth $47,000. Marshall Wace LLP bought a new position in Generation Bio in the second quarter worth $37,000. Finally, Cantor Fitzgerald L. P. acquired a new stake in Generation Bio during the third quarter worth $606,000. 95.22% of the stock is currently owned by institutional investors.

Generation Bio Price Performance

Shares of Generation Bio stock remained flat at $5.34 on Wednesday. The business’s 50-day simple moving average is $5.52 and its 200-day simple moving average is $5.62. The firm has a market cap of $35.99 million, a PE ratio of -0.57 and a beta of 2.05. Generation Bio has a 1-year low of $3.00 and a 1-year high of $8.20.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on GBIO shares. Citigroup reiterated a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Wedbush set a $5.50 price target on shares of Generation Bio and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Needham & Company LLC reissued a “buy” rating and set a $15.00 price objective on shares of Generation Bio in a research report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a research note on Thursday, January 22nd. Finally, Zacks Research raised Generation Bio to a “hold” rating in a research report on Monday, January 26th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.88.

Generation Bio Company Profile

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.